Abstract5‐Aminolevulinic acid‐based photodynamic therapy (ALA‐PDT) comprises photochemical and biological reactions, finally generating tumor destruction. Tumor selectivity of ALA‐PDT relies on the disturbed heme synthesis pathway in neoplastic cells. Tumor pretreatment with ALA induces two reactions: the first, self‐activation of the key enzyme porphobilinogen synthase and then protoporphyrin (PpIX) synthesis at low Fe++ availability. We emphasize that the toxic mechanism of ALA‐PDT triggered by 1O2 targets intracellular organelle destruction death pathways. PpIX fluorescence of tumors, particularly in glioblastoma, is used clinically for fluorescence guidance during neurosurgery. Targeting residual and metastatic cancer stem cells is a crucial challenge of ALA‐PDT, plausibly combined with other therapeutic modalities to encounter metastatic recurrences. We overview the different aspects of ALA‐PDT mechanism and future research and prospects.

AbstractThe growing numbers of pathogenic bacteria acquiring multidrug resistance are posing the challenges to develop novel therapeutic approaches. Photodynamic bacterial inactivation assaults multiple subcellular targets of pathogenic bacteria, including Staphylococcus aureus, with low tendency to induce further resistance. A wide range of aPDI photosensitizers were investigated for localized infections, including endogenous porphyrins and encapsulated sensitizers in nanoparticles. This mini review presents the concepts of aPDI, a field consisting of more than 3000 research articles published over 30 years. Mutated PBP membrane enzymes of multiantibiotic resistant S. aureus are plausible targets of aPDI. Synergistic aPDI using simultaneously DP, light irradiation and the antibiotic oxacillin, was recently described, eliminating temporarily oxacillin resistance. Additive antimicrobial effects were achieved with DP‐aPDI combined with additional classes of antibiotics. We propose that mutual aPDI adjuvant with antibiotics or other toxic molecules is opening a new therapeutic window for topical life‐threatening infections, without induction of further resistance.

Multi-drug resistance of breast cancer is a major obstacle in chemotherapy of cancer treatments. Recently it was suggested that photodynamic therapy (PDT) can overcome drug resistance of tumors. ALA-PDT is based on the administration of 5-aminolevulinic acid (ALA), the natural precursor for the PpIX biosynthesis, which is a potent natural photosensitizer. In the present study we used the AlaAcBu, a multifunctional ALA-prodrug for photodynamic inactivation of drug resistant MCF-7/DOX breast cancer cells. Supplementation of low doses (0.2mM) of AlaAcBu to the cells significantly increased accumulation of PpIX in both MCF-7/WT and MCF-7/DOX cells in comparison to ALA, or ALA + butyric acid (BA). In addition, our results show that MCF-7/DOX cells are capable of producing higher levels of porphyrins than MCF-7/WT cells due to low expression of the enzyme ferrochelatase, which inserts iron into the tetra-pyrrol ring to form the end product heme. Light irradiation of the AlaAcBu treated cells activated efficient photodynamic killing of MCF-7/DOX cells similar to the parent MCF-7/WT cells, depicted by low mitochondrial enzymatic activity, LDH leakage and decreased cell survival following PDT. These results indicate that the pro-drug AlaAcBu is an effective ALA derivative for PDT treatments of multidrug resistant tumors.

Successful 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) is dependent on efficient porphyrin synthesis in the inflicted cancer tissue, which is regulated by several enzymes. Irradiation of the tumor excites the light-sensitive porphyrins and results in ROS production and cell death. In this study we investigated the effect of the expression levels of two main enzymes in heme biosynthesis, ALA dehydratase (ALAD) and porphobilinogen deaminase (PBGD), on the capacity of K562 cells to undergo cell death following ALA-PDT. We manipulated PBGD and ALAD expression levels by shRNAs and PBGD overexpressing plasmid. PBGD down-regulation induced an elevation in ALAD activity, while overexpression of PBGD reduced ALAD activity, indicating a novel regulation feedback of PBGD on ALAD activity. This feedback mechanism enabled partial PpIX synthesis under PBGD silencing, whereas ALAD silencing reduced PpIX production to a minimum. ALA-PDT efficacy was directly correlated to PpIX levels. Thus, only ALAD-silenced cells were not affected by ALA+ irradiation, while following PBGD silencing, the accumulated PpIX, though decreased, was sufficient for successful ALA-PDT. The alterations in ALAD activity level initiated by changes in PBGD expression indicates PBGD’s central role in heme synthesis. This enables efficient ALA-PDT, even when PBGD is not fully active. Conversely, ALAD loss resulted in reduced PpIX synthesis and consequently failure in ALA-PDT, due to the absence of compensation mechanism for ALAD.

BackgroundStaphylococcus aureus is a major pathogen in clinical microbiology. It is known to cause infections at various body sites and can be life-threatening. The development of resistance to many well-established antibiotic treatments and the prevalence of methicillin-resistant S. aureus (MRAS) among hospital patients and the general community pose challenges in treating the pathogen. The antimicrobial effect of photodynamic therapy (PDT) has been a subject of study for a long time and can offer new strategies for dealing with resistant strains. ObjectiveIn our study, we searched for a positive synergistic relationship between PDT and the standard antibiotics used to treat S. aureus and MRSA infections. Materials and MethodsThe phototoxic profile of deuteroporphyrin (DP) in both resistant and susceptible clinical strains of S. aureus was determined by plating of treated and untreated broth cultures. Electron microscopy imaging was done to explore possible sites of damage and free-radical accumulation in the cells during DP-PDT. Minimal inhibitory concentration (MIC) of oxacillin, gentamicin, vancomycin, rifampin, and fusidic acid was determined using the broth dilution method, and the checkerboard method was used to detect and evaluate the synergistic potential of DP-PDT and antibiotic combinations. A synergistic combination was further characterized using broth cultures and plating. ResultsDP-PDT using a light dose of 15J/cm(2) showed a bactericidal effect even with a small concentration of 17M DP. Transmission electron microscopy indicated profound damage in the cell wall and cell membrane, and the appearance of mesosome-like structures. Free radicals tend to localize in the cell membrane and inside the mesosome. No synergistic effect was detected by combining PDT with gentamicin, vancomycin, rifampin, and fusidic acid treatments. A positive synergistic effect was observed only in DP-PDT-oxacillin combined treatment using the checkerboard method. The effect was observed in clinical antibiotic-resistant isolates after DP-PDT using a light dose of 46J/cm(2) and small concentrations of DP. Oxacillin MIC decreased below 2g/ml in resistant strains under such conditions. Cultures which did not undergo new cycles of DP-PDT recovered their original oxacillin resistance after a few generations. ConclusionsPDT with porphyrins shows possible new therapeutic options in treating drug-resistant S. aureus at body sites suitable for irradiation. The synergistic effect of DP-PDT with oxacillin on clinical strains illustrates the potential of PDT to augment traditional antibiotic treatment based on cell wall inhibitors. Lasers Surg. Med. 50:535-551, 2018. (c) 2018 Wiley Periodicals, Inc.

In mouse models of skin cancer, high-dose oral vitamin D3 (VD3; cholecalciferol) combined with photodynamic therapy (PDT) can improve the clearance of squamous precancers (actinic keratoses [AKs]).To determine whether oral VD3 can improve the clinical efficacy of a painless PDT regimen in humans with AK.The baseline lesion counts and serum 25-hydroxyvitamin D3 levels were determined. In group 1, 29 patients underwent gentle debridement and 15-minute aminolevulinic acid preincubation with blue light (30 minutes; 20 J/cm2). In group 2, 29 patients took oral VD3 (10,000 IU daily for 5 or 14 days) prior to debridement and PDT. Lesion clearance was assessed at 3 to 6 months.In group 1, the mean clearance rates of facial AK were lower in patients with VD3 deficiency (25-hydroxyvitamin D3 level < 31 ng/dL; clearance rate, 40.9% ± 42%) than in patients with normal 25-hydroxyvitamin D3 levels (62.6% ± 14.2%). High-dose VD3 supplementation (group 2) significantly improved the overall AK lesion response (72.5% ± 13.6%) compared with that in group 1 (54.4% ± 22.8%). No differences in side effects were noted.Nonrandomized trial design (interventional cohort matched to registry-based controls).Oral VD3 pretreatment significantly improves AK clinical responses to PDT. The regimen appears promising and well tolerated.

Anemia is a major cause of morbidity and mortality worldwide resulting from a wide variety of pathological conditions. In severe cases it is treated by blood transfusions or injection of erythroid stimulating agents, e.g., erythropoietin (Epo), which can be associated with serious adverse effects. Therefore, there is a need to develop new treatment modalities. We recently reported that treatment of erythroleukemic cells with the novel the bi-functional prodrugs of 5-aminolevulinic acid (ALA) and butyric acid (BA), AN233 and AN908, enhanced hemoglobin (Hb) synthesis to a substantially higher level than did ALA and BA individually or their mixture. Herein, we describe that these prodrugs when given orally to mice induced histone deacetylase inhibition in the kidneys, bone marrow and spleen, thus, indicating good penetrability to the tissues. In mice where anemia was chemically induced, treatment with the prodrugs increased the Hb, the number of red blood cells (RBCs) and the percentage of reticulocytes to normal levels. The prodrugs had no adverse effects even after repeated treatment at 100-200mg/kg for 50days. The lack of increased levels of Epo in the blood of mice that were treated with the prodrugs suggests that AN233 and AN908 affected the Hb and RBC levels in an Epo-independent manner. Taken together with our previous studies, we propose that the prodrugs increase globin expression by BA inhibition of histone deacetylase and elevation heme synthesis by ALA. These results support an Epo-independent approach for treating anemia with these prodrugs.

s of Lectures (in alphabetical order) ..................................................................................................... 1 DNA damage enhances drug survival through non-mutation effects ............................................................... 2 Naama Barkai, Gilad Yaakov 2 Epigenetic programming links intestinal inflammation to colon cancer .......................................................... 3 Yehudit Bergman 3 Pathway – Based Personalized Analysis of Cancer ........................................................................................... 4 Eytan Domany 4 Systems medicine for novel avenues into cancer diagnostics and therapy ....................................................... 5 Roland Eils 5 Organizing principles of dynamic T cell responses – from noisy cells to predictable populations ................ 6 Nir Friedman 6 A microRNA and its spouse in p53-Mdm2 circuitry .......................................................................................... 7 Eithan Galun 7 Embryonic stem cell (ES)-specific enhancers specify the expression potential of ES genes in cancer........... 8 Asaf Hellman 8 MYC, tumor heterogeneity and treatment response .......................................................................................... 9 Thomas Höfer 9 A CRISPR/Cas9-based mouse melanoma model to study immunotherapies and phenotypic plasticity ..... 10 Michael Hölzel 10 Epigenetic reprogramming by environmental exposure early in life and consequence for disease risk ..... 11 Irina Lehmann 11 Transcription regulation: from the identification of functional elements to predicitve computational models................................................................................................................................................................... 12 Uwe Ohler 12 Integrative analysis of deregulated epigenetic networks in chronic lymphocytic leukemia ......................... 13 Karsten Rippe 13 Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality ............................. 14 Eytan Ruppin 14 Epigenetic memory in development and cancer ............................................................................................... 15 Amos Tanay 15 Abstracts of Posters ............................................................................................................................................ 16s of Posters ............................................................................................................................................ 16 miRNA High-Throughput Functional Screening Identifies Several Potential Tumour Suppressive miRNAs in Neuroblastoma ................................................................................................................................. 17 Elena Afanasyeva, Frank Westermann, Kristina Iljin, Saija Haapa-Paananen, Holger Erfle 17 Metastatic potential and invasion-related forces in breast cancer cells ......................................................... 18 Martha B. Alvarez-Elizondo and Daphne Weihs 18 eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's transcriptome and signaling ............................................................................................................................................................... 19 Attar-Schneider Oshrat, Drucker Liat, Zismanov Victoria, Tartakover Matalon Shelly, Lishner M 19 Multi-microRNA-sensitive oncolytic measles virus vectors ............................................................................. 20 Marc-Andrea Baertsch, Mathias Felix Leber, Sascha Bossow, Martin Singh, Christine E. Engeland, Jessica Albert, Christian Grossardt, Dirk Jäger, Christof von Kalle and Guy Ungerechts 20 Role of histone mutations in brain tumors ........................................................................................................ 21 Pablo Bellvís, Weijun Feng, Muhammad Amir Khan, Zhe Zhu, Peng Zou, Olga Bernhardt, Hai-Kun Liu 21 T cell immune responses generate diversity through linear cell-fate progression ......................................... 22 Michael Flossdorf, Veit Buchholz, Patricia Graef, Dirk Busch, Thomas Höfer 22 Epigenetic mechanism in retinoic acid sensitive and resistant neuroblastoma cells ..................................... 23 Moritz Gartlgruber, Franziska Paul, Daniel Dreidax, Christina Schröder, Ido Amit, Frank Westermann 23 Pdots Nanoparticles Load Photosensitizers and Enhance Efficiently their Photodynamic Effect by FRET .............................................................................................................................................................................. 24 Elina Haimov, Hana Weitman, Debby Ickowicz, Zvi Malik and Benjamin Ehrenberg 24 Modeling MAPK pathway alterations in pilocytic astrocytoma ......................................................................... 25 Stefan Kallenberger, Daniel Hübschmann, Johanna Dickmann, Roland Eils 25 Tumor stress signals contribute to tumor Resistance to Antiangiogenic Therapy ........................................ 26 Adi Karsch-Bluman, Ofra Benny 26 The mutant p53-cancer stem cells paradigm .................................................................................................... 29 Tom Kaufman, Yoav Shetzer, Gabriela Koifman, Noa Rivlin, Gilad Landan, Amos Tanay and Varda Rotter 29 Unexpected complexity of miRNA-mediated regulation of breast cancer progression by isomiRs – an example ................................................................................................................................................................ 30 Cindy Koerner, Omar Salem, Ewald Muenstermann, Heike Wilhelm, Angelika Woerner, Stefan Wiemann 30 MYCN-dependent heterogeneity in cell cycle entry in neuroblastoma .......................................................... 31 Erika Kuchen, Emma Bell, Andres Florez, Chunxuan Shao, Nathalie Harder, Tatjana Ryl, Karl Rohr, Frank Westermann, Thomas Höfer 31 A novel method for high resolution mapping of T cell receptor repertoires for characterization of pubic sequences associated with selfrelated immunity............................................................................................. 32 Michal Mark 32 Early transcription dynamics during stem cell differentiation ....................................................................... 33 Yaron Mosesson, William Hamilton, Josh Brickman and Naama Barkai 33 Identification of Breast Cancer Subtypes Using RNA-Seq Data..................................................................... 34 Dvir Netanely, Ron Shamir 34 Construction of a novel target module for redirecting universal CARs against PSCA positive cells .......... 35 Elham Pishali Bejestani, Malte von Bonin, 2, , Marc Cartellieri, Armin Ehninger, Mechthild Krause, , Michael Baumann , Michael Bachmann 4, 6 35 Identifying regulators of the telomerase employing Mixed Integer Linear Programming approaches ...... 36 Alexandra Poos, André Maicher, Anna Dieckmann, Marcus Oswald, Katharina Deeg, Roland Eils, Karsten Rippe, Martin Kupiec, Brian Luke, Rainer König 36 Characterization of the tumor-infiltrating lymphocyte (TIL) repertoire in melanoma and pancreatic cancer ................................................................................................................................................................... 37 I. Poschke, M. Faryna, M. Volkmar, M. Floßdorf, M. Diken, J. Hassel, O. Strobel, F. Bergmann, T. Höfer, U. Sahin, R. Offringa 37 The lineage oncogene MITF antagonizes a proinflammatory cell state by repressing AP-1 ........................ 38 Riesenberg S., Landsberg J., Bald T., Aymans P., Kohlmeyer J., Reinhardt J.1, Goding C.R., Tüting T., Hölzel M. 38 Epigenetic silencing of MHC class I chain-related protein A and B in Merkel cell carcinoma: Improved immune recognition after reversal ..................................................................................................................... 39 Cathrin Ritter, Kaiji Fan, Kelly G. Paulson, David Schrama, Jürgen C. Becker 39 Yakir Rottenberg, Aviad Zick, Micha Barchana, Tamar Peretz 40 Klotho a novel tumor suppressor in colon cancer ............................................................................................ 41 Rubinstein T., Shahmoon S., Har Zahav G., Skalka N., Etan T., Arbesfeld R., Pasmanik-Chor M., Rubinek T. and Wolf I. 41 The role of anti-apoptotic Bcl-2 proteins for colorectal cancer development and progression .................... 42 Anna-Lena Scherr, Bruno Christian Köhler and Henning Schulze-Bergkamen 42 The multifaceted effects of primary tumor excision on breast cancer metastasis and their inhibition by COX inhibition and a β-adrenergic blockade ................................................................................................... 43 Lee Shaashua, Shamgar Ben-Eliyahu 43 miR-122*, the passenger strand of miR-122, acts as a tumor suppressor by targeting Mdm2 .................... 44 Alina Simerzin, Elina Zorde-Khvalevsky, Mila Rivkin, Revital Adar, Tania Roskams, Olivier Govaere, Sagit Arbel-Alon, Moshe Oren, Hilla Giladi, Eithan Galun 44 Epigenetic yardstick for cognitively and emotionally healthy aging as applied to cancer ............................ 45 Rotem Vered, Gil Atzmon, Gal Richter Levin, Einat Levy-Gigi 45 List of Speakers ................................................................................................................................................... 48 List of Participants .............................................................................................................................................. 49 Coordinators of the Cancer Research Schools ................................................................................................. 51 Scientific Organizing Committee .....................................................

A new type of nanoparticles, Pdots, and a new methodology of photosensitization are developed to achieve a more efficient photodynamic effect in aqueous solutions and in cells. Pdots are nano-sized particles, composed of conjugated chromophoric polymers coated with PEGylated phospholipids. They exhibit good aqueous colloidal properties, a broad absorption band and a strong and narrow emission band. We show that these characteristics improve biological photosensitization, which is employed in the photodynamic therapy of cancer. Amphiphilic photosensitizers such as Rose Bengal partition, non-covalently but with a high affinity, into the amphiphilic coating of the Pdots, without necessitating covalent attachment. At this close contact, very efficient fluorescence resonance energy transfer (FRET) occurs between the Pdot donor and the sensitizer acceptor. The Pdots serve as broad-band collectors of light, which is funneled, via energy transfer, to the photosensitizer. Therefore, energy transfer from them can additively assist in the activity of the acceptors of energy. The energy transfer mechanism, strong uptake of the Pdot-sensitizer dyads by MCF-7 adenocarcinoma cells and their enhanced photosensitized killing are demonstrated.

Abstract5-Aminolevulinic acid (ALA)-induced photodynamic therapy (ALA-PDT) has achieved remarkable research accomplishments over the past 30 years, yet its application in medical oncology still awaits clear recognition as a valid alternative therapeutic modality. It is well documented that topical ALA-PDT enables the treatment of multiple skin lesions simultaneously, and provides excellent cosmetic results with no acquired multi-drug resistance (MDR). Furthermore, upon disease recurrence the treatment can be repeated resulting in the same therapeutic efficacy. Additionally, in oncological surgery, ALA fluorescence-guided resection is a practical and simple method for visualizing intra-operative brain and urological tumors with millimeter accuracy. The urgent challenge is to direct future research of ALA-phototherapy and fluorescence diagnosis to the maturation of their medical status in oncology. Therefore, the future objectives are to amplify critical evidence-based results of ALA-PDT safety and efficacy and to validate its unique advantages over other technologies. Strong statistical PDT documentation and the positive predictive values of protoporphyrin IX (PpIX)-guided surgery will persuade the medical community to implement ALA-based therapeutics into standard clinical and surgical oncology practice. Research must address the phenomenon that no MDR develops as a consequence of PDT, since MDR is the major stumbling block in oncological therapeutics. A feasible goal should be to improve ALA administration protocols based on recent knowledge that preactivation of the enzyme porphobilinogen deaminase enhances PpIX accumulation in cancer cells and photodestruction. Moreover the recent introduction of multifunctional ALA prodrugs that maximize photosensitizer biosynthesis, targeting multiple sub-cellular targets, may increase PDT anti-cancer efficacy in additional disease settings. In conclusion, well-documented clinical results, new ALA delivery protocols, and novel multifunctional ALA prodrugs may advance ALA-PDT to becoming a front-line cancer therapy.

Photodynamic therapy (PDT) of cancer involves inflicting lethal damage to the cells of malignant tumors, primarily by singlet oxygen that is generated following light-absorption in a photosensitizer molecule. Dysfunction of cells is manifested in many ways, including peroxidation of cellular components, membrane rupture, depolarization of electric potentials, termination of mitochondrial activity, onset of apoptosis and necrosis and eventually cell lysis. These events do not necessarily occur in linear fashion and different types of damage to cell components occur, most probably, in parallel. In this report we measured the relative rates of damage to two cellular membranes: the plasma membrane and the mitochondrial membrane. We employed photosensitizers of diverse hydrophobicities and used different incubation procedures, which lead to their different intra-cellular localizations. We monitored the damage that was inflicted on these membranes, by employing optical probes of membrane integrity, in a multi-color FACS experiment. The potentiometric indicator JC-1 monitored the electric cross-membrane potential of the mitochondria and the fluorometric indicator Draq7 monitored the rupture of the plasma membrane. We show that the electric depolarization of the mitochondrial membrane and the damage to the enveloping plasma membrane proceed with different kinetics that reflect the molecular character and intracellular location of the sensitizer: PpIX that is synthesized in the cells from ALA causes rapid mitochondrial damage and very slow damage to the plasma membrane, while externally added PpIX has an opposite effect. The hydrophilic sensitizer HypS_4 can be taken up by the cells by different incubation conditions, and these affect its intracellular location, and as a consequence either the plasma membrane or the mitochondria is damaged first. A similar correlation was found for additional extracellularly-provided photosensitizers HP and PpIX.

Anemia is a major clinical symptom of a wide variety of pathological conditions a common related to reduced erythropoiesis. Whereas erythropoietin treatment showed an improvement in the patients' condition, it revealed increased risks of thromboembolic and cardiovascular events. Herein we describe stimulation of erythropoiesis by the multifunctional 1-(butyryloxy)ethyl-5-amino-4-oxopentanoate, (AlaAcBu), a 5-aminolevulinic-acid (ALA) derivative, which undergoes metabolic hydrolysis yielding two erythroid differentiation inducers, ALA and butyric acid (BA), each acting through a different mechanism. ALA, the first precursor in the heme biosynthesis, accelerates heme synthesis and BA, a histone deacetylase inhibitor (HDACI) that activates the transcription of globin mRNA. Our results show that the AlaAcBu mutual prodrug is a potent chemical differentiation inducer of K562 human erythroleukemia cells manifested by augmentation of heme and globin synthesis and assembly of hemoglobin. Exposure of K-562 cells to AlaAcBu resulted in an increase in heme synthesis and globin expression. Stimulation of the heme pathway was evident by the over-expression of porphobilinogen deaminase (PBGD) and ferrochelatase. AlaAcBu promoted cellular erythroid differentiation depicted by the expression of the marker glycophorin A and cellular maturation characterized by cytoplasm hemoglobinization, polar arrangement of mitochondria and a developed central vacuolar system preceding nuclear extrusion. The ability of AlaAcBu to promote differentiation along the erythroid lineage and to dramatically induce hemoglobin synthesis presented in this report.

Recently a mini-spectrometer with a handheld probe quantifying 5-aminolevulinic acid (5-ALA) based fluorescence intensity of brain tumors was developped by Kim et al. to improve fluorescence-guided neurosurgery.To evaluate if this new tool is capable to discriminate nuances of fluorescence intensity of strongly fluorescing tumors (glioblastomas (GBM) and meningiomas (MM)). To study different modes of measurement (touch/no-touch). To determine protoporphyrin IX (PPIX) concentration in tumor tissue as compared to a laboratory spectrometer.The tumor tissue was resected from patients operated in the neurosurgical department of University Hospital Duesseldorf, Germany between 01/2014 and 06/2014. Two spectrometers, one custom-built with a handheld probe (“mini-spectrometer”) and one commercial laboratory spectrometer were employed. After calibration they were used to detect and compare fluorescence intensity of human brain tumor samples ex vivo under standardized conditions. The mini-spectrometer was tested at different distances to the tumor. PPIX concentrations of tumor lysates were determined by both spectrometers.In total n = 11 tumors (5 MM and 6 GBM) resulting in 17 tumor biopsies were studied. All GBM showed significant higher fluorescence intensity as compared to MM (Z = −3.123, p = 0.001). The fluorescence signal was inversely proportional to the square of the distance (GBM: R2 = 0.226; F = 4.683; p < 0.5; MM: R2 = 0255; F = 8.042; p < 0.01). The mini-spectrometer recorded fluorescence signals up to 2 mm (“no-touch”). Determination of PPIX concentration in tumor by the mini-spectrometer did not differ from a laboratory spectrometer.The mini-spectrometer was a very sensitive tool for detection of 5-ALA based fluorescence of human brain tumors. Fluorescence intensity of glioblastoma and meningioma were significantly different. A no-touch mode of measurement was possible. PPIX concentration in tumor tissue could be determined as precisely as with a laboratory spectrometer. In future clinical trials the practicability of using such a tool in vivo has to be further evaluated.

5-Aminolevulinic acid mediated −photodynamic therapy (ALA-PDT) is known to be effective in treating acne vulgaris and other sebaceous gland-related diseases. However, the therapeutic mechanisms of ALA-PDT still remain undetermined. In this study, we aimed to investigate the effects and mechanisms of ALA-PDT on the cell growth and lipogenesis of human SZ95 sebocytes.Human SZ95 sebocytes were treated with different concentration of ALA-PDT.CCK-8 assay was used to detect cell proliferation activity. Fluorescence microscope and flow cytometry were used to observe the secretion of lipids in SZ95 cells after Nile red staining. Western blotting was used to detect and analyze the protein expression level of P-p70 S6 K/p70 S6 K, P-4E-BP1/4E-BP1, SREBP-1, PPARγ, P-mTOR/mTOR, and P-Raptor/Raptor. Mean while, mTOR pathway activator IGF-1 and mTORC1 inhibitor rapamycin were added to observe the interferences on the ALA-PDT treatment of SZ95 cells.ALA-PDT suppressed the cell growth and reduced the secretion of lipids in a dose-dependent manner in SZ95 cells. ALA-PDT reduced the protein levels of P-p70 S6 K (T389), SREBP-1, PPARγ, P-mTOR and P-Raptor. IGF-1 had counter effects on ALA-PDT, and rapamycin enhanced the effects of ALA-PDT in SZ95 cells in suppressing the cell growth and reducing the secretion of lipids.ALA-PDT suppressed the cell growth in SZ95 cells by mTOR-p70 S6K(T389) signaling and reduced the lipogenesis in SZ95 cells by mTOR-SREBP-1/PPARγ signaling. Sebaceous glands atrophy and reduction of sebum secretion after ALA-PDT may be caused by the suppression of lipogenesis and cell growth in sebocytes.

The novel reporters, unimodal FT-IR-traceable, bimodal fluorescent and FT-IR-traceable hybrid silica (SiO2) nanoparticles (NPs), were prepared using the Stober methodology. Initially, the basic Stober cohydrolysis of tetraethoxysilane (TEOS) and of the iron-complexed alkyl-triethoxysilane (EtO)(3)Si-L-(eta(4)-2E, 4E-dienyl)-Fe(CO)(3)(0) (L = alkyl linker, DIT-tag reagent 3) afforded unimodal 13.7 +/- 2 nm-sized SiO2@DIT-tag(60) NPs. These NPs can incorporate an organometallic FT-IR sensitive (eta(4)-2E, 4E-dienyl)-tricarbonyliron(0) complex moiety which acts as a sensitive FT-IR traceable species due to the strong iron complex nu(FeC)equivalent to O vibrational bands that appear in the 1996-2063 cm(-1) region, a region free of any parasitic band. The sensitivity of the FT-IR-based detection of SiO2@DIT-tag(60) NPs has been determined using incremental mixtures of B16 melanoma cell lysates as a biological medium model. The detection limit was found to be 0.190 mu g of Fe per mg of B16 cell lysate. In the second step, bimodal hybrid fluorescent and FT-IR-traceable 35.7 +/- 5 nm sized SiO2@DIT-tag(20)@FITC NPs were similarly fabricated, in order to enable both fluorescence and FT-IR spectroscopy detection. This has been readily obtained through the straightforward co-incorporation of an additional fluorescein-containing alkyl-triethoxysilane conjugate FITC-APTES (FITC: fluorescein isothiocyanate, APTES: (3-aminopropyl)triethoxysilane). Subsequent surface modification with APTES of the resulting SiO2@DIT-tag(20)@FITC NPs afforded amine functionalized 34.4 +/- 6 nm-sized SiO2@ DIT-tag(20)@FITC@NH2 NPs that were readily endocytosed by B16 melanoma cells. All these novel hybrid silica NPs have been fully characterized by FT-IR spectroscopy, high resolution TEM/SEM (HR-TEM/SEM) with elemental energy-dispersive X-ray spectroscopy (compositional EDAX analysis), dynamic light scattering (DLS), zeta potential measurements, and inductively coupled plasma-optical emission spectroscopy (ICP-OES). Preliminary biological studies demonstrated the non-toxicity of the NPs. No observable modification in the B16 cells' morphology or mortality was seen after the internalization of SiO2@DIT-tag(20)@FITC@NH2 NPs.

Skin cancer is considered a risky worldwide disease. Traditional treatments have several weaknesses, necessitating the creation of more effective treatments. In this case, photodynamic therapy and nanotechnology were used to demonstrate their therapeutic efficacy as combinational approaches in treating different types of skin cancer. In this review, we will discuss the photoexcitation mechanism of PDT, its cell destruction capability, and give a comprehensive outlook of the different photosensitizer types. Also, light sources and their properties will be addressed. Further, we will present some of the nanoparticles used as delivery systems in the skin and show their ideal characteristics for the effective delivery of drugs for skin cancer therapy. Finally, the review aims to cover topics from the most recent reported preclinical studies and clinical trials about nanoparticles loaded with different drugs and triggered with PDT to treat different types of skin cancer. The review will demonstrate that photodynamic therapy and nanoparticles have contributed to the great evolution of skin cancer treatment by having an effective therapeutic efficiency in treating different types of skin cancer such as melanoma, squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and actinic keratosis (AK) which shows the need of using them instead of traditional technologies.